SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Lab advances on the bourses

06 Dec 2019 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 2943.20, up by 73.05 points or 2.55% from its previous closing of Rs. 2870.15 on the BSE.

The scrip opened at Rs. 2925.00 and has touched a high and low of Rs. 2945.00 and Rs. 2874.30 respectively. So far 16003 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2990.00 on 27-Nov-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.

Last one week high and low of the scrip stood at Rs. 2969.00 and Rs. 2850.00 respectively. The current market cap of the company is Rs. 48776.66 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.

Dr. Reddy's Laboratories has launched Bortezomib for Injection 3.5 mg/vial, approved by the US Food and Drug Administration (USFDA) via a 505(b) (2) new drug application (NOA) pathway for intravenous use only.

The company’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

Dr. Reddys Lab Share Price

1213.00 -7.75 (-0.63%)
22-Apr-2026 10:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1657.45
Dr. Reddys Lab 1213.00
Cipla 1226.90
Zydus Lifesciences 926.15
Lupin 2298.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×